Investigative ophthalmology & visual science · 2012
Predicting glaucomatous progression in glaucoma suspect eyes using relevance vector machine classifiers for combined structural and functional measurements.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Bowd Christopher, Lee Intae, Goldbaum Michael H, Balasubramanian Madhusudhanan, Medeiros Felipe A, Zangwill Linda M, Girkin Christopher A, Liebmann Jeffrey M, Weinreb Robert N
Аннотация
PURPOSE: The goal of this study was to determine if glaucomatous progression in suspect eyes can be predicted from baseline confocal scanning laser ophthalmoscope (CSLO) and standard automated perimetry (SAP) measurements analyzed with relevance vector machine (RVM) classifiers.
METHODS: Two hundred sixty-four eyes of 193 participants were included. All eyes had normal SAP results at baseline with five or more SAP tests over time. Eyes were labeled progressed (n = 47) or stable (n = 217) during follow-up based on SAP Guided Progression Analysis or serial stereophotograph assessment. Baseline CSLO-measured topographic parameters (n = 117) and baseline total deviation values from the 24-2 SAP test-grid (n = 52) were selected from each eye. Ten-fold cross-validation was used to train and test RVMs using the CSLO and SAP features. Receiver operating characteristic (ROC) curve areas were calculated using full and optimized feature sets. ROC curve results from RVM analyses of CSLO, SAP, and CSLO and SAP combined were compared to CSLO and SAP global indices (Glaucoma Probability Score, mean deviation and pattern standard deviation).
RESULTS: The areas under the ROC curves (AUROCs) for RVMs trained on optimized feature sets of CSLO parameters, SAP parameters, and CSLO and SAP parameters combined were 0.640, 0.762, and 0.805, respectively. AUROCs for CSLO Glaucoma Probability Score, SAP mean deviation (MD), and SAP pattern standard deviation (PSD) were 0.517, 0.513, and 0.620, respectively. No CSLO or SAP global indices discriminated between baseline measurements from progressed and stable eyes better than chance.
CONCLUSIONS: In our sample, RVM analyses of baseline CSLO and SAP measurements could identify eyes that showed future glaucomatous progression with a higher accuracy than the CSLO and SAP global indices. (ClinicalTrials.gov numbers, NCT00221897, NCT00221923.).
METHODS: Two hundred sixty-four eyes of 193 participants were included. All eyes had normal SAP results at baseline with five or more SAP tests over time. Eyes were labeled progressed (n = 47) or stable (n = 217) during follow-up based on SAP Guided Progression Analysis or serial stereophotograph assessment. Baseline CSLO-measured topographic parameters (n = 117) and baseline total deviation values from the 24-2 SAP test-grid (n = 52) were selected from each eye. Ten-fold cross-validation was used to train and test RVMs using the CSLO and SAP features. Receiver operating characteristic (ROC) curve areas were calculated using full and optimized feature sets. ROC curve results from RVM analyses of CSLO, SAP, and CSLO and SAP combined were compared to CSLO and SAP global indices (Glaucoma Probability Score, mean deviation and pattern standard deviation).
RESULTS: The areas under the ROC curves (AUROCs) for RVMs trained on optimized feature sets of CSLO parameters, SAP parameters, and CSLO and SAP parameters combined were 0.640, 0.762, and 0.805, respectively. AUROCs for CSLO Glaucoma Probability Score, SAP mean deviation (MD), and SAP pattern standard deviation (PSD) were 0.517, 0.513, and 0.620, respectively. No CSLO or SAP global indices discriminated between baseline measurements from progressed and stable eyes better than chance.
CONCLUSIONS: In our sample, RVM analyses of baseline CSLO and SAP measurements could identify eyes that showed future glaucomatous progression with a higher accuracy than the CSLO and SAP global indices. (ClinicalTrials.gov numbers, NCT00221897, NCT00221923.).